Trevor Clancy

Researcher with interests in immuno-oncology related bioinformatics

[bioRxiv @biorxivpreprint]

Deep learning of antibody epitopes using molecular permutation vectors https://t.co/Eo7lY1vZde #bioRxiv

[Trevor Clancy @Trevor_Clancy]

The heterogeneity and rarity of sarcomas makes it challenging to develop successful therapies for sarcoma patients. This research addresses the need to develop further insights into potential biomarkers that may determine which patients are most likely... https://t.co/yH0HBKES0d

[Trevor Clancy @Trevor_Clancy]

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy https://t.co/0ouaoQyla7 via @Bakersfieldcali

[CEPI @CEPIvaccines]

CEPI støtter norske NEC @OncoImmunity som bruker kunstig intelligens i utviklingen av en bredspektret betakoronavaksine @DagensMedisin 🇳🇴 https://t.co/pLUa8dW9yD

[NEC OncoImmunity AS @OncoImmunity]

A major milestone for our team! Congrats to all involved
https://t.co/WdzPynuTLP

[NEC OncoImmunity AS @OncoImmunity]

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets: Press Releases | NEC https://t.co/836qm7kVrv

[NEC OncoImmunity AS @OncoImmunity]

https://t.co/qKbOYxMiT2

[NEC OncoImmunity AS @OncoImmunity]

We are hiring!
Looking for talented people to use their data science and software skills in the fight against cancer and infectious diseases.
https://t.co/SQupknT0Tf

[Trevor Clancy @Trevor_Clancy]

@OncoImmunity is hiring!
Looking for talented people to use their data science and software skills in the fight against cancer and infectious diseases.
https://t.co/obc3xZTdmS

[NEC OncoImmunity AS @OncoImmunity]

Exciting to see our AI approach to develop universal blueprints for vaccine design now published in the peer review journal Scientific Reports https://t.co/czhYXtGkcO

[NEC OncoImmunity AS @OncoImmunity]

An artificial intelligence T-cell diagnostic test for COVID-19 https://t.co/bfqaZzod1Q

[NEC OncoImmunity AS @OncoImmunity]

NEC’s AI-driven Blueprint for a Safe, Universally Effective New Coronavirus Vaccine: Business Insights | NEC https://t.co/8q6aperD0o

[MalmbergLab @MalmbergLab]

Our "NK cell proliferomics" paper is out in @CellReports Congrats @AlinePfefferle "Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity" https://t.co/s5yzZKlne3

[Trevor Clancy @Trevor_Clancy]

https://t.co/2pGUQN0bTv

[Trevor Clancy @Trevor_Clancy]

https://t.co/BJrcEOt9Ii

[Inven2as @Inven2as]

Vår porteføljebedrift Ultimovacs har hentet inn 370 millioner kroner i en overtegnet emisjon, og vil bli notert på Oslo Børs mandag 3. juni 2019 https://t.co/XSgQTYd2hj @OsloCancer @radforsk @Oslounivsykehus @UniOslo

[Trevor Clancy @Trevor_Clancy]

https://t.co/gUk7JbfOPd

[MalmbergLab @MalmbergLab]

scRNA-seq reveals heterogeneity in the CD56bright NK cell subset and nondramatic transitioning into CD56dim NK cells @Trevor_Clancy @AlinePfefferle and Herman Netskar https://t.co/o7n0BvPj6S

[Trevor Clancy @Trevor_Clancy]

OncoImmunity was pleased to present exciting results on improved neoantigen presentation and immunogenicity at the #NeoAg Summit today https://t.co/N9XYiRdBAB

[Trevor Clancy @Trevor_Clancy]

https://t.co/rNoiTXSPmb